Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors

Omicron and its subvariants have rendered most authorized monoclonal antibody-based treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ineffective, highlighting the need for biologics capable of overcoming SARS-CoV-2 evolution. These mostly ineffective antibodies target vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Weidenbacher, Payton A.-B., Waltari, Eric, de los Rios Kobara, Izumi, Bell, Benjamin N., Morris, Mary Kate, Cheng, Ya-Chen, Hanson, Carl, Pak, John E., Kim, Peter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596371/
https://www.ncbi.nlm.nih.gov/pubmed/36076082
http://dx.doi.org/10.1038/s41589-022-01140-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596371/
https://www.ncbi.nlm.nih.gov/pubmed/36076082
http://dx.doi.org/10.1038/s41589-022-01140-1

Ejemplares similares